Viking therapeutics wikipedia Subcutaneous VK2735 will advance straight into a phase 3 trial, and Viking Therapeutics, Inc. 31, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. m. Board of Directors Lawson Macartney, DVM, Ph. The company was founded by Brian Lian Jan 6, 2025 · Viking Therapeutics, Inc. Nov 13, 2024 · Viking Therapeutics (VKTX-1. , a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, today announced that it has obtained an exclusive worldwide license to five novel therapeutic programs from Ligand Pharmaceuticals Incorporated (NASDAQ: LGND). Oct 31, 2024 · SAN DIEGO, Oct. Track Viking Therapeutics Inc (VKTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. 61%) are both up-and-coming biotechs with no sales revenue, plenty of cash in the bank, big catalysts on the horizon, and pipeline Nov 4, 2024 · (RTTNews) - Viking Therapeutics Inc. 13, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. Their realm was bordered by powerful tribes to the south. 69, compared to $62. Since the company lacks a marketed drug in its portfolio, we do not expect it to record revenues. When there's an event that provides new information about the company's 5 days ago · Get the Latest News and Ratings for VKTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter. S. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that clinical data from the company's VK2735 obesity program will be highlighted in two poster presentations Sep 23, 2012 · Viking Therapeutics, Inc. 65%). (VKTX) stock discussion in Yahoo Finance's forum. Eli Lilly (LLY) is speculated to be one of the companies pursuing a takeover of Viking Therapeutics Lab analysis shows positive results from therapies created by Viking. The company was founded by Brian Lian Jan 10, 2022 · SAN DIEGO, Jan. Nov 13, 2023 · SAN DIEGO, Nov. 46 dollars the previous day. (VKTX) on Sunday issued positive early results in the trial of its experimental obesity pill VK2735, reports said, citing a presentation at the ObesityWeek Jan 10, 2022 · SAN DIEGO, Jan. 7, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. Macartney has served as the Chairperson of our Board since May 2015 and as a member of our Board since May 2014. 26 as of Friday, December 27 2024. Hanley and S. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new results from the company's Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD Viking Therapeutics General Information Description. The company's clinical Oct 17, 2024 · Viking Therapeutics is having a monstrous year, with its shares up over 240% thus far. Viking Therapeutics stock price forecast for January 2025. 100% free, no signups. 50, 64. currently has an average brokerage recommendation (ABR) of 1. 19, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. SAN DIEGO, Oct. Viking Therapeutics' stock is down 25% due to competition in the obesity treatment market, despite promising Phase 2 results for VK2735. Maximum price 43. During its third-quarter earnings call a few weeks ago, Viking's 6 days ago · Viking Therapeutics, Inc. We have announced positive top-line results from our 12-week, proof-of-concept Phase 2 clinical trial of VK5211 in patients who recently suffered a hip fracture. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. 26%) has been one of the hottest healthcare stocks of 2024. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. 26%) and Summit Therapeutics (SMMT-3. The company was founded by Brian Lian Jan 17, 2025 · Get a complete stock price history for Viking Therapeutics, starting from its first trading day. 3 In the U. . Tons of financial metrics for serious investors. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Viking Therapeutics, Inc. on Sunday issued positive early results in the trial of its experimental obesity pill VK2735, reports said, citing a presentation at the ObesityWeek meeting. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of new results from the ongoing Phase 2b clinical trial of VK2809, the company's novel Jun 4, 2024 · That sent Viking’s shares down by as much as 15%, according to William Blair. Share your opinion and gain insight from other stock traders and investors. VK2735 (Subcutaneous & Oral Formulations) Dual GLP-1/GIP Receptor Agonist Obesity and Metabolic Disorders Overview & Profile. 4, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. 00 per share. Viking Therapeutics has at least two (maybe four?) major catalysts ahead. 10, 2022 /PRNewswire/ -- Viking Therapeutics, Inc. The company reported quite encouraging clinical results from a version of its Nov 4, 2024 · Viking Therapeutics is rowing its longboat toward the front of the oral obesity therapy race, posting detailed phase 1 data that suggest its dual agonist of GLP-1 and GIP can hold its own in a 5 days ago · Viking Therapeutics Inc is a healthcare service provider. P. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. VK2809 (formerly known as MB07811) is a thyromimetic prodrug whose active form is selective for the THR-β isoform. General Information Business Development Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. (VKTX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives Oct 28, 2024 · Viking Therapeutics' VK2735 drug shows promising weight-loss results, driving a stock rally and positive analyst sentiment. 24 dollars. The forecast for beginning 40. 91% above the 52 week low of 20. Up to 78% reductions in Liver fat. 92 set on Jan 26, 2024. Feb 28, 2024 · SAN DIEGO, Feb. B. Así funciona. co/fees for details. Nov 10, 2024 · Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today's highest-growth healthcare markets: weight loss drugs. The clinical-stage company will provide updates on its GLP-1/GIS drug Feb 29, 2024 · El fármaco para adelgazar de Viking Therapeutics muestra en ensayos preliminares mayor pérdida de peso en menos tiempo que Ozempic o Wegovy. 12, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies Nov 4, 2024 · Viking Therapeutics also unveiled promising results for its injection. 5 million people, have high LDL cholesterol. In 2001, Nov 4, 2024 · By Steve GoldsteinCiara Linnane . The pe ratio is not a useful metric when the company is not profitable. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that results from the company's Phase 2b clinical trial of VK2809, the company's novel liver-selective Oct 11, 2024 · Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. Contact. Oct 24, 2024 · Viking Therapeutics (NASDAQ: VKTX) was an outlier on the stock exchange Thursday, in the best way possible. General Information Nov 18, 2024 · 1. 49, minimum 29. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that data from the company's Phase 1 Nov 4, 2024 · This past spring, Viking reported preliminary Phase 1 data for oral VK2735 showing an average placebo-adjusted weight loss of 3. [43] Oct 13, 2024 · Viking Therapeutics (VKTX-1. It is being developed by Viking Therapeutics in a phase II trial for the treatment of nonalcoholic steatohepatitis [1][2] and is also being investigated for glycogen storage disease type Ia. Equities Equities USA Viking Therapeutics Inc is a healthcare service provider. We are developing a unique series of novel dual agonists of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders such as obesity, NASH, and certain rare disorders. In a study that tested the highest dosage of 100-mg, the drug — known as KV2735 — resulted in an average of 6. May 22, 2024 · Up 260% so far this year, shares of Viking Therapeutics (VKTX 0. Lian serves as our President and Chief Executive Officer, and as a director. (VKTX) has recently grabbed the spotlight with its GLP-1 drug candidate, VK2735, showing positive clinical outcomes. Shares of the company have risen by 285% thus far, and that's even factoring in a recent pullback in price Feb 7, 2024 · SAN DIEGO, Feb. VK2735 is a dual agonist of the GLP-1 receptor and GIP receptor, with a similar mechanism of action as tirzepatide, which acts on the same receptors. 10, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. The average target predicts an increase of 219. Analysts say the treatment, which is being tested in both oral and injectable forms Vikings under Leif Erikson, heir to Erik the Red, reached North America and set up short-lived settlements in present-day L'Anse aux Meadows, Newfoundland, Canada. In the U. 8% body weight reduction after 28 days compared to placebo. 4 NAFLD can lead to NASH, a severe form which involves inflammation and cell damage. 46. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster presentations Oct 31, 2024 · Viking Therapeutics has been one of the best-performing biopharmaceutical stocks in 2024. Viking Therapeutics Inc. Get 20 years of historical peg ratio charts for VKTX stock and other companies. 3 and approximately 31. One of the most potent SARMs so far. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that final results from the company's Phase 2b clinical trial of VK2809, the company's novel liver-selective VK2809Selective Thyroid Receptor-β Agonist NASH and Lipid Disorders Overview & Profile We are developing a unique series of selective thyroid hormone receptor beta (TRβ) agonists for metabolic disorders. In that study Oct 28, 2024 · SAN DIEGO, Oct. See insights on Viking Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. SAN DIEGO, March 28, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. 1,2,3 Top-line data showed that the trial achieved its primary endpoint, demonstrating statistically significant, dose dependent increases in lean body mass On July 15, 2019, members of the Viking Therapeutics team visited the Nasdaq MarketSite in New York’s Times Square to ring the opening bell. 59%) is a hot biotech stock thanks to the company's record of reporting good data from its cardiometabolic disease programs, and there's no sign of that reputation Viking Therapeutics, Inc. Jun 24, 2024 · SAN DIEGO, June 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine Feb 27, 2024 · SAN DIEGO, Feb. 2% in a month at a 100 mg dose . Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. Mar 28, 2023 · Expands Potential Opportunities for VK2735 with Highly Differentiated Dosing Option. Our lead clinical program’s drug candidate, VK2809, […] President and Chief Executive Officer Dr. The company was founded by Brian Lian You can buy and sell Viking Therapeutics (VKTX) and other stocks, ETFs, and their options commission-free on Robinhood with real-time quotes, market data, and relevant news. The Apr 24, 2024 · SAN DIEGO, April 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. 75, with a low estimate of 74 and a high estimate of 138. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced Viking Therapeutics WKN A12GD6 ISIN US92686J1060. The biotech Mar 26, 2024 · Shares of Viking Therapeutics jumped over 25% in early trading Tuesday after the company reported positive results in a test of its experimental weight-loss treatment. 6% at least partly amid some takeover speculation. Other Robinhood Financial fees may apply, check rbnhd. If one of its drugs obtains approval, the stock could easily rally even higher, especially since having a Nov 4, 2024 · For high-profile biotech Viking Therapeutics (VKTX-1. A negative value means this company has been losing money. Prior to joining Viking Therapeutics, he was a Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, where he was responsible for coverage of small and mid-cap biotechnology companies with an emphasis on the diabetes, oncology, infectious disease, and Novel therapeutics for metabolic and endocrine disorders. [4] Founded in 1987 as Progenix Inc. Oral GLP-1 drug in study led to average weight loss of 8. The company noted that higher doses of its oral tablet formulation increased patients' weight loss beyond earlier formulations. ET today. But as wise investors know Nov 4, 2024 · Viking Therapeutics shares reversed course to fall 8% on Monday as focus shifted to the drug developer's ability to mass produce its oral obesity treatment that was shown to be safe and effective Brian Lian is President/CEO at Viking Therapeutics Inc. Preliminary clinical data suggest VK0612 has […] Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. Share your ideas and get valuable insights from the community of like minded traders and investors Find the latest Viking Therapeutics, Inc. Nov 12, 2024 · Results to be Featured in Oral Late Breaker Presentation. 7% of American adults, or 73. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. 3% after 28 days. , a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Presents at 43rd Annual J. See the company profile for Viking Therapeutics, Inc. 28%) are a hot commodity thanks to its increasingly promising therapies in development to treat obesity. May 25, 2024 · If you're looking at up-and-coming healthcare stocks with significant potential in the anti-obesity market, one company you've likely come across is Viking Therapeutics (VKTX 2. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has initiated a Phase 1 clinical study Jan 24, 2024 · Get the peg ratio charts for Viking Therapeutics (VKTX). SAN DIEGO, Nov. LGD-4033, also known by the developmental code name VK5211 and by the black-market name Ligandrol, is a selective androgen receptor modulator (SARM) which is under development for the treatment of muscle atrophy in people with hip fracture. 00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy Oct 21, 2024 · Viking Therapeutics VKTX is set to report third-quarter earnings on Oct. [65] Viking expansion into continental Europe was limited. Includes open, high, low, close and volume. , the number of patients with hypercholesterolemia is estimated to be greater than 100 million. General Information 4 days ago · On Friday, Viking Therapeutics Inc (VKTX:NAQ) closed at 34. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive data from the company's Phase 1b clinical trial of VK0214, a novel small molecule agonist of the 1 day ago · The 12 analysts with 12-month price forecasts for Viking Therapeutics stock have an average target of 106. 13: Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity Jan. It is injectable and is being developed by Viking Therapeutics. Clinical Data. VK2735 to Advance to Phase 3 for Obesity; End-of-Phase 2 Meeting Planned for 2H24; Oral VK2735 Phase 2 Study in Obesity Expected to Begin 4Q24 Jul 25, 2024 · Summary. 48. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies, sending down shares of A high-level overview of Viking Therapeutics, Inc. Overview We have a pipeline of novel, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to […] Nov 19, 2024 · SAN DIEGO, Nov. ; Chairman Dr. In June 2021, Viking initiated a Phase 1b clinical trial of VK0214 in patients with Oct 17, 2023 · SAN DIEGO, Oct. D. SAN DIEGO, CA, May 22, 2014 – Viking Therapeutics, Inc. LGD Jun 4, 2024 · Viking Therapeutics, Inc. Ligand Pharmaceuticals Incorporated is a biopharmaceutical company located in San Diego, California. Viking, which launched in 2012, is a small TR-Beta Agonist VK2809 (MB07811) in Hypercholesterolemic Subjects. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced Nov 12, 2024 · SAN DIEGO, Nov. More than 4 days ago · Viking Therapeutics, Inc. The company's clinical Nov 19, 2024 · Viking Therapeutics Presents Results from Phase 2b VOYAGE Study of VK2809 in Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024 Nov 28, 2024 · Viking Therapeutics (VKTX 3. When clinical trials are completed potentially by mid spring you are not going to be able to buy this penny stock for this bargain. According to the research reports of 13 Wall Street equities research Viking Therapeutics (NASDAQ:VKTX) rose 6. In those results, the highest of the five doses Oct 4, 2024 · The rise of Viking Therapeutics also spells trouble for Pfizer stock as the pharma giant struggles to become relevant in the fast-growing drug market. Within its latest earnings release, the biotech had some encouraging news to report, and Sep 29, 2024 · One of the current stars of the biotech world is Viking Therapeutics (VKTX-1. VK0214 has been granted orphan drug designation by the FDA for the treatment of X-ALD. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced 1 day ago · Viking Therapeutics, Inc. Schoenfeld, Viking Therapeutics, San Diego, CA Abstract Background: Thyroid hormone is a key regulator of lipoprotein metabolism, particularly acting via the beta isoform of nuclear T3 receptor in liver. [24] Corporate governance. 04% from the current stock price of 33. Data Anticipated in 2H2023. 08: CI Oct 17, 2023 · Viking Therapeutics Presents New Data from Phase 1 Clinical Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Oral Presentation at ObesityWeek 2023 Jul 25, 2024 · Viking Therapeutics shares soared by more than 30% early Thursday after the company told investors it’s moving an experimental obesity drug into Phase 3 testing earlier than expected and exploring more convenient dosing. 1 day ago · Viking Therapeutics stock closed at 33. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2024, and provided an update on In September 2020, Acadia Pharmaceuticals acquired clinical-stage biotechnology company CerSci Therapeutics. 23, after market close. General Information Nov 4, 2024 · /PRNewswire/ -- Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic O n Tuesday, Viking Therapeutics (NASDAQ: VKTX), a clinical-stage biotech specializing in treatments for metabolic diseases, saw its stock price surge by a staggering 121% in response to a Feb 27, 2024 · Viking Therapeutics, Inc. Initially focused on developing its own drugs, a period of turbulence in the early 2000s culminated in its CEO being ejected by the shareholders and provoked a change in focus to the acquisition of existing drugs and Jul 25, 2024 · Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. , NAFLD affects up to 25% of the population. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's Phase 2 clinical trial of VK2735, a dual agonist of the Jan 9, 2025 · Viking Therapeutics VKTX announced that it has started the phase II VENTURE-Oral Dosing study to evaluate the safety and efficacy of the oral version of its investigational obesity drug VK2735. , the company went public in 1992. [1][2][3] ^ Mariam E Sunny, Bhanvi Satija (2024-02-27). 26%), and for good reason. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on its clinical . Averaged Viking Therapeutics stock price for the month 36. Lian, R. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced Oct 10, 2023 · Presentation to Highlight VK2735's Preliminary Safety, Tolerability, and Pharmacodynamic Effects in Healthy Volunteers . (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and Oct 9, 2024 · SAN DIEGO, Oct. The medicine, dubbed VK2735, has already shown promising results in a Phase 2 trial released in February. Jun 3, 2024 · SAN DIEGO, June 3, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. It is also one of the strongest. With obesity and metabolic disorders on the rise, Viking's entry into this space could mark a significant turning point. This is the most common SARM you will see talked about. Jul 25, 2024 · An Ozempic rival is getting closer to market — and it's hurting Novo Nordisk and Eli Lilly stock Stock in Viking Therapeutics, the maker of the new treatment, soared almost 40% May 22, 2015 · The p/e ratio for Viking Therapeutics (VKTX) stock is -44. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive 52-week histologic data from its Phase 2b VOYAGE study of VK2809, the company's novel liver Print PDF. This expansion occurred during the Medieval Warm Period. From January 2017 to […] Jul 24, 2024 · SAN DIEGO, July 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. 82. Although the In June 2014, he shorted the stock of Ligand Pharmaceuticals, criticizing its business practices in a 56-page report alleging fraud and insolvency [41] and focusing on the drug Promacta and its relationship to Viking Therapeutics. See Brian Lian's compensation, career history, education, & memberships. Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Find the latest Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at several upcoming investor conferences. Viking is developing VK0214, which is also a novel, orally available small molecule thyroid hormone receptor agonist that possesses selectivity for the beta receptor subtype. provided a better-than-expected pipeline update when it reported second quarter earnings. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the initiation of a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735, a novel dual agonist of the glucagon-like Oct 28, 2024 · Viking Therapeutics, Inc. [14] [10] [8] As of March 2023, LGD-4033 (VK5211) continues to be under development by Viking Therapeutics and continues to be in phase 2 clinical trials for treatment of muscle atrophy and hip fracture. [3] Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced Dec 17, 2024 · Summary. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the pricing of its underwritten public offering of 6,471,000 shares of its common stock at a price to the public of $85. 26%) is a clinical-stage pharma company that's been eyeing the weight loss market for some time now. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2024, and provided an update Nov 4, 2024 · Viking Therapeutics presented at the ObesityWeek meeting on Sunday, noting “promising” early results for its experimental obesity pill, with increased weight loss at higher doses, IBD’s Ed Carson reports. [42] He also wrote letters to Congress regarding the alleged abuses. 26%), Monday was very much a good news/bad news kind of day. The company was founded by Brian Lian Originally discovered/developed by Ligand Pharmaceuticals and currently under development by Viking Therapeutics. The Die Viking Therapeutics Inc Aktie wird unter der ISIN US92686J1060 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, NASDAQ, London, Bats, BX World, gettex, Tradegate, Lang Fatty Liver Disease and Hypercholesterolemia. (VKTX) stock. (VKTX) on Sunday issued positive early results in the trial of its experimental obesity pill VK2735, reports said, citing a presentation at the ObesityWeek Jan 9, 2023 · San Diego–based Viking Therapeutics has sued a group of companies, as well as their common founder and CEO, Jinzi Jason Wu, for allegedly stealing the trade secrets of a clinical-stage oral drug Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. 4 days ago · Viking Therapeutics, Inc. 17, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ET, the shares had dropped 10% to $55. The study showed "stellar" weight loss from weeks 12 to 16, Leerink Partners analyst Thomas Smith said in a report. Oct 29, 2024 · Viking Therapeutics has 5 employees at their 1 location. Biotech stocks tend to be catalyst-driven. Morgan Healthcare Conference 2025, Jan-13-2025 01:30 PM Jan. It was also under development for the treatment of cachexia, hypogonadism, and osteoporosis, but development for these indications was discontinued. General Information Nov 4, 2024 · Viking Therapeutics shares fell Monday after reporting the latest results from trials of its weight-loss drugs. The clinical-stage company is advancing to the later stages of developing a drug that, if Nov 4, 2024 · Viking Therapeutics Inc. 27 at close yesterday. (Nasdaq:VKTX) is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and endocrine disorders. Learn more on VKTX stock here. Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Nov 12, 2024 · Viking Therapeutics, Inc. Nov 4, 2024 · (RTTNews) - Viking Therapeutics Inc. General Information Viking Therapeutics, Inc. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. Nov 4, 2024 · SAN DIEGO, Nov. cheered analysts Monday after the biotech Oct 24, 2024 · Following an end-of-Phase II meeting with the FDA in the fourth quarter, Viking Therapeutics plans to push its subcutaneous obesity therapy VK2735 into late-stage development and to start a Phase II trial for an oral formulation. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2023, and provided an update on its Nov 4, 2024 · Obesity pill data released by Viking Therapeutics Inc. Oct 23, 2024 · SAN DIEGO, Oct. Mar 16, 2024 · Viking Therapeutics (VKTX-1. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine Jul 24, 2024 · Conference call scheduled for 4:30 p. 9, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. VK0612Fructose-1,6-bisphosphatase (FBPase) Inhibitor Type 2 Diabetes Overview & Profile VK0612 is a first-in-class, orally available drug candidate for type 2 diabetes, one of the largest global healthcare challenges today. Nov 4, 2024 · Viking Therapeutics presented at the ObesityWeek meeting on Sunday, noting “promising” early results for its experimental obesity pill, with increased weight loss at higher doses, IBD’s Ed Nov 4, 2024 · Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage biopharma announced Monday. Viking Therapeutics Inc is a healthcare service provider. As of 1:14 p. Viking Therapeutics Share Price Prediction For Next Months and Years. 23, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX) stock quote, history, news and other vital information to help you with your stock trading and investing. oqwn knmgucnh zdwqkrzl xdgik htrpgqs kzaoy vzca cvyv ubyus qcau